These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36599608)

  • 1. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.
    Maron MS; Masri A; Choudhury L; Olivotto I; Saberi S; Wang A; Garcia-Pavia P; Lakdawala NK; Nagueh SF; Rader F; Tower-Rader A; Turer AT; Coats C; Fifer MA; Owens A; Solomon SD; Watkins H; Barriales-Villa R; Kramer CM; Wong TC; Paige SL; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Abraham T;
    J Am Coll Cardiol; 2023 Jan; 81(1):34-45. PubMed ID: 36599608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Maron MS; Masri A; Nassif ME; Barriales-Villa R; Arad M; Cardim N; Choudhury L; Claggett B; Coats CJ; Düngen HD; Garcia-Pavia P; Hagège AA; Januzzi JL; Lee MMY; Lewis GD; Ma CS; Michels M; Olivotto I; Oreziak A; Owens AT; Spertus JA; Solomon SD; Tfelt-Hansen J; van Sinttruije M; Veselka J; Watkins H; Jacoby DL; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Abraham TP;
    N Engl J Med; 2024 May; 390(20):1849-1861. PubMed ID: 38739079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
    Coats CJ; Masri A; Nassif ME; Barriales-Villa R; Arad M; Cardim N; Choudhury L; Claggett B; Düngen HD; Garcia-Pavia P; Hagège AA; Januzzi JL; Lee MMY; Lewis GD; Ma CS; Maron MS; Miao ZM; Michels M; Olivotto I; Oreziak A; Owens AT; Spertus JA; Solomon SD; Tfelt-Hansen J; van Sinttruije M; Veselka J; Watkins H; Jacoby DL; German P; Heitner SB; Kupfer S; Lutz JD; Malik FI; Meng L; Wohltman A; Abraham TP;
    J Am Heart Assoc; 2024 Aug; 13(15):e035993. PubMed ID: 39056349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial.
    Tian Z; Li L; Li X; Wang J; Zhang Q; Li Z; Peng D; Yang P; Ma W; Wang F; Jin W; Cheng X; Sun J; Fu Y; Lyu C; Zhang S
    JAMA Cardiol; 2023 Oct; 8(10):957-965. PubMed ID: 37639259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy.
    Dybro AM; Rasmussen TB; Nielsen RR; Andersen MJ; Jensen MK; Poulsen SH
    J Am Coll Cardiol; 2021 Dec; 78(25):2505-2517. PubMed ID: 34915981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
    Desai MY; Owens A; Geske JB; Wolski K; Saberi S; Wang A; Sherrid M; Cremer PC; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Balasubramanyam A; Lampl K; Sehnert AJ; Nissen SE
    Circulation; 2023 Mar; 147(11):850-863. PubMed ID: 36335531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Hypertrophic Cardiomyopathy: A Meta-Analysis and Systematic Review.
    Yassen M; Changal K; Busken J; Royfman R; Schodowski E; Venkataramany B; Khouri SJ; Moukarbel GV
    Am J Cardiol; 2024 Jan; 210():219-224. PubMed ID: 37884110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Sebastian SA; Padda I; Lehr EJ; Johal G
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):519-532. PubMed ID: 37526885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
    Hegde SM; Lester SJ; Solomon SD; Michels M; Elliott PM; Nagueh SF; Choudhury L; Zemanek D; Zwas DR; Jacoby D; Wang A; Ho CY; Li W; Sehnert AJ; Olivotto I; Abraham TP
    J Am Coll Cardiol; 2021 Dec; 78(25):2518-2532. PubMed ID: 34915982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
    Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.
    Masri A; Sherrid MV; Abraham TP; Choudhury L; Garcia-Pavia P; Kramer CM; Barriales-Villa R; Owens AT; Rader F; Nagueh SF; Olivotto I; Saberi S; Tower-Rader A; Wong TC; Coats CJ; Watkins H; Fifer MA; Solomon SD; Heitner SB; Jacoby DL; Kupfer S; Malik FI; Meng L; Sohn RL; Wohltman A; Maron MS;
    J Card Fail; 2024 Mar; ():. PubMed ID: 38493832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial.
    Wang A; Spertus JA; Wojdyla DM; Abraham TP; Nilles EK; Owens AT; Saberi S; Cresci S; Sehnert A; Lakdawala NK
    JACC Heart Fail; 2024 Mar; 12(3):567-579. PubMed ID: 37855754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy.
    Tian Z; Wang F; Jin W; Zhang Q; Zhou J; Yang P; Wang G; Hsu P; Sun J; Zhang S; Han Y
    BMJ Open; 2023 Jun; 13(6):e071473. PubMed ID: 37336533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.
    Heitner SB; Jacoby D; Lester SJ; Owens A; Wang A; Zhang D; Lambing J; Lee J; Semigran M; Sehnert AJ
    Ann Intern Med; 2019 Jun; 170(11):741-748. PubMed ID: 31035291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring treatment with cardiac myosin inhibitors in symptomatic obstructive hypertrophic cardiomyopathy.
    Chatur S; Hegde SM
    Curr Opin Cardiol; 2023 Sep; 38(5):424-432. PubMed ID: 37382090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCM.
    Masri A; Barriales-Villa R; Elliott P; Nassif ME; Oreziak A; Owens AT; Tower-Rader A; Heitner SB; Kupfer S; Malik FI; Melloni C; Meng L; Wei J; Saberi S;
    Eur J Heart Fail; 2024 Jul; ():. PubMed ID: 39023326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
    Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy.
    Fananapazir L; Epstein ND; Curiel RV; Panza JA; Tripodi D; McAreavey D
    Circulation; 1994 Dec; 90(6):2731-42. PubMed ID: 7994815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort.
    Rader F; Oręziak A; Choudhury L; Saberi S; Fermin D; Wheeler MT; Abraham TP; Garcia-Pavia P; Zwas DR; Masri A; Owens A; Hegde SM; Seidler T; Fox S; Balaratnam G; Sehnert AJ; Olivotto I
    JACC Heart Fail; 2024 Jan; 12(1):164-177. PubMed ID: 38176782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design.
    Coats CJ; Maron MS; Abraham TP; Olivotto I; Lee MMY; Arad M; Cardim N; Ma CS; Choudhury L; Düngen HD; Garcia-Pavia P; Hagège AA; Lewis GD; Michels M; Oreziak A; Owens AT; Tfelt-Hansen J; Veselka J; Watkins HC; Heitner SB; Jacoby DL; Kupfer S; Malik FI; Meng L; Wohltman A; Masri A;
    JACC Heart Fail; 2024 Jan; 12(1):199-215. PubMed ID: 38032573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.